Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
A 
Agilent Technologies Inc (A)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/14/2025: A (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
20 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $136.51
1 Year Target Price $136.51
| 9 | Strong Buy |
| 2 | Buy |
| 9 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -22.09% | Avg. Invested days 32 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/14/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 35.02B USD | Price to earnings Ratio 30.36 | 1Y Target Price 136.51 |
Price to earnings Ratio 30.36 | 1Y Target Price 136.51 | ||
Volume (30-day avg) 20 | Beta 1.23 | 52 Weeks Range 96.23 - 153.19 | Updated Date 07/13/2025 |
52 Weeks Range 96.23 - 153.19 | Updated Date 07/13/2025 | ||
Dividends yield (FY) 0.84% | Basic EPS (TTM) 4.06 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 17.59% | Operating Margin (TTM) 23.56% |
Management Effectiveness
Return on Assets (TTM) 8.46% | Return on Equity (TTM) 18.88% |
Valuation
Trailing PE 30.36 | Forward PE 19.92 | Enterprise Value 37028499667 | Price to Sales(TTM) 5.28 |
Enterprise Value 37028499667 | Price to Sales(TTM) 5.28 | ||
Enterprise Value to Revenue 5.59 | Enterprise Value to EBITDA 21.05 | Shares Outstanding 284064992 | Shares Floating 282982441 |
Shares Outstanding 284064992 | Shares Floating 282982441 | ||
Percent Insiders 0.29 | Percent Institutions 91.56 |
Upturn AI SWOT
Agilent Technologies Inc
Company Overview
History and Background
Agilent Technologies Inc. was founded in 1999 as a spin-off from Hewlett-Packard. It initially focused on test and measurement solutions and has evolved to become a leader in life sciences, diagnostics, and applied chemical markets.
Core Business Areas
- Life Sciences and Applied Markets Group (LSAG): Provides application-focused solutions that include instruments, software, consumables, and services that enable customers to identify, quantify, and analyze the physical and biological properties of substances and products.
- Diagnostics and Genomics Group (DGG): Offers solutions to improve patient outcomes by accelerating results in the lab, informing diagnoses, and personalizing treatment in areas such as pathology, oncology, and infectious diseases.
- Agilent CrossLab Group (ACG): Provides laboratory-wide services, including instrument maintenance and repair, qualification and validation services, education, and consumables, such as columns and supplies.
Leadership and Structure
Agilent is led by CEO Padraig McDonnell. The company operates with a functional structure across its business segments and corporate functions like finance, HR, and R&D.
Top Products and Market Share
Key Offerings
- Liquid Chromatography-Mass Spectrometry (LC/MS): Agilent's LC/MS systems are used for chemical analysis and detection. Market share is estimated around 20-25%. Revenue from this product is a significant contributor to LSAG. Competitors include Waters Corporation, Thermo Fisher Scientific, and SCIEX.
- Market Share (%): 22
- Gas Chromatography (GC): Agilent's GC systems are used for separating and analyzing volatile substances. The market share is approximately 30%. Competitors include Thermo Fisher Scientific, PerkinElmer, and Shimadzu.
- Market Share (%): 30
- Market Share (%): 35
- Microarrays: Agilent's microarray solutions are used for gene expression analysis and genomics research. Agilent leads this market alongside Illumina, Inc. Competitors include Illumina, Thermo Fisher Scientific.
Market Dynamics
Industry Overview
The analytical and life science instrumentation market is growing, driven by advancements in healthcare, pharmaceuticals, and environmental monitoring. Increased regulatory scrutiny and R&D investments also contribute to market expansion.
Positioning
Agilent is a leading player with a strong brand reputation and a comprehensive product portfolio. Its competitive advantages include technological innovation, global presence, and customer service.
Total Addressable Market (TAM)
The total addressable market is approximately $60 billion, and Agilent is well positioned to capture a significant portion, focusing on high-growth areas like biopharma and diagnostics.
Upturn SWOT Analysis
Strengths
- Strong brand reputation
- Comprehensive product portfolio
- Global presence
- Technological innovation
- Strong customer relationships
Weaknesses
- High reliance on R&D investments
- Sensitivity to economic cycles
- Competition from larger diversified companies
Opportunities
- Expansion into emerging markets
- Growth in biopharma and diagnostics
- Increasing demand for personalized medicine
- Strategic acquisitions
Threats
- Intense competition
- Economic downturns
- Technological obsolescence
- Regulatory changes
Competitors and Market Share
Key Competitors
- WAT
- TMO
- ILMN
Competitive Landscape
Agilent's advantages include its comprehensive product portfolio and strong customer relationships. However, it faces intense competition from larger, more diversified companies like Thermo Fisher Scientific.
Major Acquisitions
Resolution Bioscience
- Year: 2021
- Acquisition Price (USD millions): 550
- Strategic Rationale: Expansion of Agilent's diagnostics and genomics portfolio with liquid biopsy-based solutions.
BioTek Instruments
- Year: 2019
- Acquisition Price (USD millions): 1050
- Strategic Rationale: Expanded Agilent's cell analysis portfolio.
Growth Trajectory and Initiatives
Historical Growth: Agilent has achieved steady growth through organic initiatives and strategic acquisitions.
Future Projections: Analysts project continued revenue and earnings growth for Agilent, driven by its strong market position and favorable industry trends.
Recent Initiatives: Recent initiatives include investments in R&D, acquisitions of complementary businesses, and expansion into new markets.
Summary
Agilent Technologies is a strong player in the life sciences and diagnostics market with a diverse product portfolio and a good track record of growth. The company benefits from its brand reputation and technological innovation. They are however, in a highly competitive market, and need to proactively manage threats such as economic volatility and technological changes.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (10-K, 10-Q)
- Analyst reports
- Industry publications
- Company Website
Disclaimers:
This analysis is based on publicly available information and represents a general overview. It should not be considered financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Agilent Technologies Inc
Exchange NYSE | Headquaters Santa Clara, CA, United States | ||
IPO Launch date 1999-11-18 | CEO, President & Director Mr. Padraig McDonnell | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 18000 | Website https://www.agilent.com |
Full time employees 18000 | Website https://www.agilent.com | ||
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies. This segment also offers GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies. The Diagnostics and Genomics segment provides genomics, contract manufacturing and research and development, pathology, companion diagnostics, reagent partnership, and biomolecular analysis businesses; and cell analysis plate based assays, flow cytometers, real-time cell analyzers, cell imaging systems, microplate readers, and related consumables. The Agilent CrossLab segment provides various services, including repairs, parts, maintenance, installations, training, compliance support, software as a service, asset management, and consulting services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.